Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgenâs Neulasta to help reduce the risk of infection after intense chemotherapy.
äŒæ¥ã³ãŒãPODD
äŒç€ŸåInsulet Corp
äžå Žæ¥May 15, 2007
æé«çµå¶è²¬ä»»è
ãCEOãMcevoy (Ashley)
åŸæ¥å¡æ°3900
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«May 15
æ¬ç€Ÿæåšå°100 Nagog Park
éœåžACTON
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·01720-3440
é»è©±çªå·19786007000
ãŠã§ããµã€ãhttps://www.omnipod.com
äŒæ¥ã³ãŒãPODD
äžå Žæ¥May 15, 2007
æé«çµå¶è²¬ä»»è
ãCEOãMcevoy (Ashley)